Evidence-Based Immunology and Infectious Disease

The Economics of Resistant Pathogens and Antibiotic Innovation | Page 4

Published Online: April 23, 2014
Michael R. McKellar, BA; Michael E. Chernew, PhD; and A. Mark Fendrick, MD
There is no magic bullet to guarantee innovation in antibiotics development. It is difficult to determine whether R&D incentives or reducing the costs of bringing new antibiotics through expedited FDA review will be sufficient. Likely, the most effective method would be to simply allow higher prices. While this could increase the total costs to payers, a strategy of limited use at a higher price could increase the value generated by the healthcare system. Moreover, an increase in price must be coupled with controls to protect against overutilization, which could exacerbate problems of resistance.

Simultaneously, strategies to reduce underutilization, which could lead to adverse health outcomes for patients, will be important also. Quality measures that capture both overuse and underuse will be necessary to promote the optimal utilization of these highly valuable medications. The ultimate policy goal is to ensure that antibiotics are both used appropriately, with the right patients receiving the right medication at the right time, and that the world has a steady stream of future antibiotics that effectively treat the resistant organisms that will inevitably emerge.

Author Affiliations: Harvard Medical School Department of Health Care Policy, Boston, MA (MRM, MEC); University of Michigan, Ann Arbor, MI (AMF).

Source of Funding: Funding for this work was provided by Cubist Pharmaceuticals. Author Disclosures: The authors (MRM, MEC, AMF) report receiving payment from Cubist for their work on this article.

Authorship Information: Concept and design (MRM, MEC, AMF); acquisition of data (MEC); analysis and interpretation of data (MEC, AMF); drafting of the manuscript (MRM, AMF); critical revision of the manuscript for important intellectual content (MRM, MEC).

Address correspondence to: Michael R. McKellar, BA, Harvard Medical School, Department of Health Care Policy, 180 Longwood Ave, Boston, MA 02115. E-mail: mckellar@hcp.med.harvard.edu.
References

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151-185.

2. Cutler CM, Meara E. Changes in the age distribution of mortality over the 20th century. NBER Working Paper Series No. 8556; October 2001.

3. Murray CK, Hsu JR, Solomkin JS, et al. Prevention and management of infections associated with combat-related extremity injuries. J Trauma. 2008;64(3 suppl):S239-S251.

4. Mullins CD, Kuznik A, Saya FT, et al. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillinresistant Staphylococcus aureus. Clin Ther. 2006;28(8):1184-1198.

5. O’Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? JAMA. 2013;310(13):1343-1344. 6. Highleyman L. Feds approve two new hepatitis C meds. The Bay Area Reporter. December 12, 2013. http://www.ebar.com/news/article.php?sec=news&article=69331. Accessed December 12, 2013.

7. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother. 2014;69(1):234-240.

8. Center for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/arthreats-2013-508.pdf. Published April 23, 2013. Accessed December 1, 2013.

9. Reddy S. Antibiotics do’s and don’ts. The Wall Street Journal. August 19, 2013. http://online.wsj.com/news/articles/SB10001424127887323423804579023113596120826. Accessed December 1, 2013.

10. Westly E. India moves to tackle antibiotic resistance. Nature. 2012;489(7415):192.

11. World Health Organization. Tuberculosis fact sheet. http://www.who.int/mediacentre/factsheets/fs104/en/. Published October 2013.Accessed December 1, 2013.

12. Smith R, Coast J. The true cost of antimicrobial resistance. BMJ. 2013;346:f1493.

13. Kent D, Polgreen PM, Beekmann S, et al. Use or preserve? how practice patterns impactupon markets for new and improved antibiotics (abx). Poster #428 presented at Infectious Diseases Society of America poster presentation session, October 5, 2007.

14. Johannsson B, Beekmann SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM. Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol. 2011;32(4):367-374.

15. McGregor JC, Rich SE, Harris AD, et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis. 2007;45(3):329-337.

16. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25-31.

17. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009;136(5):1237-1248.

18. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care
Med. 2006;34(6):1589-1596.

19. Usdin S. GAIN Act, FDA stance only first steps to refilling antibiotic pepline in U.S. Bio-Century website. http://www.biocentury.com/biotech-pharma-news/coverstory/2012-11-19/gain-act-fda-stance-only-first-steps-to-refillingantibiotic-pipeline-in-us-a1. Published November19, 2012. Accessed December 1, 2013.

20. Meier B. Pressure grows to create drugs for ‘superbugs.’ New York Times. June 2, 2013.http://www.nytimes.com/2013/06/03/health/experts-debate-plan-to-speed-antibioticdevelopment.html?emc=eta1&_r=2&. Accessed December 1, 2013.

21. New FDA task force will support innovation in antibacterial drug development [press release]. US Food and Drug Administration website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm320643.htm. Published September 24, 2012. Accessed December 1, 2013.

22. Hirshler B. Last-line antibiotics losing ability to kill superbugs in EU. Reuters website. http://in.mobile.reuters.com/article/businessNews/idINBRE9AE0L620131115. Published November 15, 2013. Accessed December 1, 2013.

23. UK 5 year antimicrobial resistance strategy 2013 to 2018. Gov.UK website. https://www.gov.uk/government/publications/uk-5-yearantimicrobial-resistance-strategy-2013-to-2018.Updated September 10, 2013. Accessed December 1, 2013.

24. Cormican M, Vellinga A. Existing classes of antibiotics are probably the best we will ever have. BMJ. 2012;344:e3369.

25. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trend in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38(9):1279-1286.

26. Conly J, Johnston B. Where are all the new antibiotics? the new antibiotic paradox. Can J Infect Dis Med Microbiol. 2005;16(3):159-160.

27. So AD, Ruiz-Esparza Q, Gupta N, Cars O. 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ. 2012;244:e1782.

28. Pray LA. Antibiotic R&D: resolving the paradox between unmet medical need and commercial incentive. Insight Pharma Reports website. http://www.insightpharmareports.com/antibiotic/overview.aspx. Published 2012. Accessed December 1, 2013.

29. Spellberg B. New antibiotic development:barriers and opportunities in 2012. Alliance for the Prudent Use of Antibiotics. 2012;30(1).http://www.tufts.edu/med/apua/news/news-newsletter-vol-30-no-1-2.shtml. Accessed December 1, 2013.

30. Gottlieb S, Carino T, Barnes L. Paying for new drugs for new bugs: regulation is only one side of the coin. AEI.org website. http://www.aei.org/files/2013/07/10/-gottliebpdf_092004305764.pdf.